200 related articles for article (PubMed ID: 17877878)
1. The varied beneficial effects of ivermectin (Mectizan) treatment, as observed within onchocerciasis foci in south-eastern Nigeria.
Anosike JC; Dozie IN; Ameh GI; Ukaga CN; Nwoke BE; Nzechukwu CT; Udujih OS; Nwosu DC
Ann Trop Med Parasitol; 2007 Oct; 101(7):593-600. PubMed ID: 17877878
[TBL] [Abstract][Full Text] [Related]
2. Maintaining compliance to ivermectin in communities in two West African countries.
Whitworth JA; Alexander ND; Seed P; Thomas W; Abiose A; Jones BR
Health Policy Plan; 1996 Sep; 11(3):299-307. PubMed ID: 10160375
[TBL] [Abstract][Full Text] [Related]
3. Influence of health education on community participation in rapid assessment of onchocerciasis prior to distribution of ivermectin.
Shu EN; Nwadike KI; Onwujekwe EO; Ugwu OC; Okonkwo PO
East Afr Med J; 1999 Jun; 76(6):320-3. PubMed ID: 10750518
[TBL] [Abstract][Full Text] [Related]
4. DISTRIBUTION AND UTILISATION OF IVERMECTIN (MECTIZAN): A CHEMOTHERAPEUTIC APPROACH TO THE CONTROL OF ONCHOCERCIASIS IN OLD OHAOZARA LGA, EBONYI STATE, EASTERN NIGERIA.
Okpara EM; Mnaemeka AM; Iyioku UU; Udoh UV
J Egypt Soc Parasitol; 2015 Dec; 45(3):663-70. PubMed ID: 26939245
[TBL] [Abstract][Full Text] [Related]
5. Onchocerciasis in Anambra State, Southeast Nigeria: clinical and psychological aspects and sustainability of community directed treatment with ivermectin (CDTI).
Mbanefo EC; Eneanya CI; Nwaorgu OC; Oguoma VM; Otiji MO; Ogolo BA
Postgrad Med J; 2010 Oct; 86(1020):573-7. PubMed ID: 20971709
[TBL] [Abstract][Full Text] [Related]
6. Progress towards the elimination of onchocerciasis as a public-health problem in Uganda: opportunities, challenges and the way forward.
Ndyomugyenyi R; Lakwo T; Habomugisha P; Male B
Ann Trop Med Parasitol; 2007 Jun; 101(4):323-33. PubMed ID: 17524247
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of onchocerciasis control in the Upper Denkyira East municipal in the forest area of Ghana: Responses of participants and distributors to the CDTI programme.
Agyemang ANO; Badu K; Baffour-Awuah S; Owusu-Dabo E; Biritwum NK; Garms R; Kruppa TF
Acta Trop; 2018 Sep; 185():357-362. PubMed ID: 29932933
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting the attrition of community-directed distributors of ivermectin, in an onchocerciasis-control programme in the Imo and Abia states of south-eastern Nigeria.
Emukah EC; Enyinnaya U; Olaniran NS; Akpan EA; Hopkins DR; Miri ES; Amazigo U; Okoronkwo C; Stanley A; Rakers L; Richards FO; Katabarwa MN
Ann Trop Med Parasitol; 2008 Jan; 102(1):45-51. PubMed ID: 18186977
[TBL] [Abstract][Full Text] [Related]
9. A multi-centre study of the effect of Mectizan treatment on onchocercal skin disease: clinical findings.
Ogbuagu KF; Eneanya CI
Ann Trop Med Parasitol; 1998 Apr; 92 Suppl 1():S139-45. PubMed ID: 9861280
[TBL] [Abstract][Full Text] [Related]
10. Reversal of amenorrhoea after Mectizan treatment.
Anosike JC; Abanobi OC
Trop Geogr Med; 1995; 47(5):222-4. PubMed ID: 8553449
[TBL] [Abstract][Full Text] [Related]
11. Ivermectin lotion (sklice) for head lice.
Early J; MacNaughton H
Am Fam Physician; 2014 Jun; 89(12):984-6. PubMed ID: 25162168
[No Abstract] [Full Text] [Related]
12. The effect of 5 years of annual treatment with ivermectin (Mectizan) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic.
Kennedy MH; Bertocchi I; Hopkins AD; Meredith SE
Ann Trop Med Parasitol; 2002 Apr; 96(3):297-307. PubMed ID: 12061976
[TBL] [Abstract][Full Text] [Related]
13. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control.
Tekle AH; Elhassan E; Isiyaku S; Amazigo UV; Bush S; Noma M; Cousens S; Abiose A; Remme JH
Parasit Vectors; 2012 Feb; 5():28. PubMed ID: 22313631
[TBL] [Abstract][Full Text] [Related]
14. Primary motives for demand of ivermectin drug in mass distribution programmes to control onchocerciasis.
Abanobi OC; Chukwuocha UM; Onwuiiliri CO; Opara KC
East Afr J Public Health; 2011 Mar; 8(1):33-7. PubMed ID: 22066280
[TBL] [Abstract][Full Text] [Related]
15. Adverse reactions from community directed treatment with ivermectin (CDTI) for onchocerciasis and loiasis in Ondo State, Nigeria.
Otubanjo OA; Adeoye GO; Ibidapo CA; Akinsanya B; Okeke P; Atalabi T; Adejai ET; Braide E
Rev Biol Trop; 2008 Dec; 56(4):1635-43. PubMed ID: 19419072
[TBL] [Abstract][Full Text] [Related]
16. Ivermectin does not reduce the burden of itching in an onchocerciasis endemic community.
Whitworth JA; Luty AJ; Maude GH; Morgan D; Downham MD; Taylor DW
Trans R Soc Trop Med Hyg; 1992; 86(3):281-3. PubMed ID: 1412653
[TBL] [Abstract][Full Text] [Related]
17. Non-adherence to community directed treatment with ivermectin for onchocerciasis control in Rungwe district, southwest Tanzania.
Lakwo TL; Gasarasi DB
East Afr Med J; 2006 Jun; 83(6):326-32. PubMed ID: 16989378
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of onchocerciasis and associated clinical manifestations in selected hypoendemic communities in Ghana following long-term administration of ivermectin.
Otabil KB; Gyasi SF; Awuah E; Obeng-Ofori D; Atta-Nyarko RJ; Andoh D; Conduah B; Agbenyikey L; Aseidu P; Ankrah CB; Nuhu AR; Schallig HDFH
BMC Infect Dis; 2019 May; 19(1):431. PubMed ID: 31101085
[TBL] [Abstract][Full Text] [Related]
19. Seasonal biting pattern of Simulium damnosum s.l and its implications on onchocerciasis treatment with ivermectin.
Adewale B; Oyerinde JP; Mafe MA
West Afr J Med; 2008 Oct; 27(4):224-9. PubMed ID: 19469400
[TBL] [Abstract][Full Text] [Related]
20. [Indication of Mectizan in human medicine other than onchocerciasis].
Richard-Lenoble D
Sante; 1998; 8(1):84-7. PubMed ID: 9592892
[No Abstract] [Full Text] [Related]
[Next] [New Search]
